Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma
Authors:
- 25 January 2014
- journal article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 140 (3) , 471-476
Abstract
Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that usually occurs in infants. It is commonly associated with Kasabach–Merritt phenomenon which is directly responsible for the significant morbidity and mortality, including hemodynamic instability, local invasion, and compression of vital structures. Treatment is particularly difficult for those who had no response to conventional therapies. This paper wants to share experience of mTOR inhibitors sirolimus in the treatment of refractory KHE. Six cases of refractory KHE were diagnosed and treated in Children’s Hospital of Fudan University from Jan 2010–June 2013; all of them were treated with sirolimus in June 2012 after failing multiple other therapies. In six patients, gender was equally distributed between male and female patients. The mean age at the time of initial diagnosed as KHE was 3.1 ± 1.8 months. All of them had been pretreated with at least 2 medical therapies. All of them showed significant improvement in clinical status with tolerable side effects. The average time to response was 5.3 ± 1.0 days; the average stabilization time of platelet was 15.1 ± 8.0 days; and the average time for sirolimus treated as single agent was 1.7 ± 0.4 months. No recurrence of their symptoms happened. Sirolimus appears to be effective and safe in patients with life-threatening KHE and represents a promising tool in treating refractory KHE.Keywords
This publication has 30 references indexed in Scilit:
- PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapyBreast Cancer Research and Treatment, 2013
- Treatment of Infantile Hemangiomas with Sirolimus in a Patient with PHACE SyndromePediatric Dermatology, 2013
- Sirolimus for the treatment of complicated vascular anomalies in childrenPediatric Blood & Cancer, 2011
- Successful Treatment of Kaposiform Hemangioendothelioma and Tufted Angioma With VincristineJournal of Pediatric Hematology/Oncology, 2010
- Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologiesDevelopmental Dynamics, 2010
- Successful Management of Kaposiform Hemangioendothelioma with Kasabach‐Merritt Phenomenon Using Vincristine and TiclopidinePediatric Dermatology, 2009
- Inhibition of the mammalian target of rapamycin impedes lymphangiogenesisKidney International, 2007
- Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasisCancer Science, 2007
- Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathyPediatric Transplantation, 2006
- D2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendotheliomaLaboratory Investigation, 2005